261734-99-0

Basic information

• Product Name: N-HYDROXY-FURAN-2-CARBOXAMIDINE
• Synonyms: N-HYDROXY-FURAN-2-CARBOXAMIDINE;N'-hydroxy-2-furancarboximidamide(SALTDATA: HCl)
• CAS NO: 261734-99-0
• Molecular Formula: C5H6N2O2
• Molecular Weight: 126.11
• Product Categories: pharmacetical
• Mol File: 261734-99-0.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 292.9°Cat760mmHg
• Flash Point: 130.9°C
• Appearance: /
• Density: 1.4g/cm³
• CAS DataBase Reference: N-HYDROXY-FURAN-2-CARBOXAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-HYDROXY-FURAN-2-CARBOXAMIDINE(261734-99-0)
• EPA Substance Registry System: N-HYDROXY-FURAN-2-CARBOXAMIDINE(261734-99-0)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 261734-99-0(Hazardous Substances Data)

Usage

General Description

N-HYDROXY-FURAN-2-CARBOXAMIDINE is a chemical compound containing a furan ring with a carboxamidine group and a hydroxyl group attached to it. It is commonly used as a reagent in organic synthesis, particularly in the preparation of heterocyclic compounds. N-HYDROXY-FURAN-2-CARBOXAMIDINE has been studied for its potential use in the pharmaceutical industry, where it has shown promise as an inhibitor of certain enzymes and as an anti-inflammatory agent. N-HYDROXY-FURAN-2-CARBOXAMIDINE is also known to have antimicrobial properties, making it a potentially useful compound in the development of new drugs and treatments. Overall, this chemical shows potential for various applications in both the pharmaceutical and chemical industries.

Upstream product

• 617-90-3 2-furancarbonitrile 

Downstream Products

• 1622348-48-4 5-(4-chloro-2-methylphenyl)-3-(furan-2-yl)-4,5-dihydro-1,2,4-oxadiazole 
• 501653-22-1 5-(chloromethyl)-3-(furan-2-yl)-1,2,4-oxadiazole 
• 61051-42-1 [3-chloro-4-[3-(2-furanyl)-1,2,4-oxadiazol-5-yl]phenyl]carbamic acid, 2,2,2-trichloroethyl ester 
• 61051-41-0 [3-Chloro-4-[3-(2-furanyl)-1,2,4-oxadiazol-5-yl]phenyl]carbamic acid, phenyl ester 
• 61051-45-4 5-(4-amino-2-chlorophenyl)-3-(2-furanyl)-1,2,4-oxadiazole 
• 96898-66-7 3-(2-furyl)-5-(4-isothiocyanophenyl)-1,2,4-oxadiazole 
• 96898-92-9 3-(furan-2-yl)-5-(4-aminophenyl)-1,2,4-oxadiazole 
• 309734-72-3 5-(furan-2-yl)-3-phenyl-1,2,4-oxadiazole 
• 1448510-52-8 3-phenyl-5-(2-furyl)-1,2,4-oxadiazole-4-oxide 
• 154345-84-3 (D,L)-3-(2-furyl)-5-(2-phenyl-1-tert-butyloxycarbonylaminoethyl)-1,2,4-oxadiazole 

Relevant articles and documents

Triaryl compound and preparation method and pharmaceutical application thereof

The invention discloses a triaryl compound as shown in a formula I which is described in the specification, physiologically acceptable salt, a preparation method of the compound, a pharmaceutical preparation containing the compound, and application of the

Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors

Thirty novel triaryl compounds were designed and synthesized based on the known proteasome inhibitor PI-1840. Most of them showed significant inhibition against the β5c subunit of human 20S proteasome, and five of them exhibited IC50 values at the sub-micromolar level, which were comparable to or even more potent than PI-1840. The most active two (1c and 1d) showed IC50 values of 0.12 and 0.18 μM against the β5c subunit, respectively, while they displayed no obvious inhibition against the β2c, β1c and β5i subunits. Molecular docking provided informative clues for the subunit selectivity. The potent and subunit selective proteasome inhibitors identified herein represent new chemical templates for further molecular optimization.

Small Molecule Inhibition of MicroRNA miR-21 Rescues Chemosensitivity of Renal-Cell Carcinoma to Topotecan

Chemical probes of microRNA (miRNA) function are potential tools for understanding miRNA biology that also provide new approaches for discovering therapeutics for miRNA-associated diseases. MicroRNA-21 (miR-21) is an oncogenic miRNA that is overexpressed in most cancers and has been strongly associated with driving chemoresistance in cancers such as renal cell carcinoma (RCC). Using a cell-based luciferase reporter assay to screen small molecules, we identified a novel inhibitor of miR-21 function. Following structure-activity relationship studies, an optimized lead compound demonstrated cytotoxicity in several cancer cell lines. In a chemoresistant-RCC cell line, inhibition of miR-21 via small molecule treatment rescued the expression of tumor-suppressor proteins and sensitized cells to topotecan-induced apoptosis. This resulted in a >10-fold improvement in topotecan activity in cell viability and clonogenic assays. Overall, this work reports a novel small molecule inhibitor for perturbing miR-21 function and demonstrates an approach to enhancing the potency of chemotherapeutics specifically for cancers derived from oncomir addiction.